Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system.

Okochi Y, Nihashi T, Fujii M, Kato K, Okada Y, Ando Y, Maesawa S, Takebayashi S, Wakabayashi T, Naganawa S.

Ann Nucl Med. 2014 Feb;28(2):94-102. doi: 10.1007/s12149-013-0787-4. Epub 2013 Nov 24.

2.

Comparison of 11C-methionine PET and 18F-FDG PET in patients with primary central nervous system lymphoma.

Kawase Y, Yamamoto Y, Kameyama R, Kawai N, Kudomi N, Nishiyama Y.

Mol Imaging Biol. 2011 Dec;13(6):1284-9. doi: 10.1007/s11307-010-0447-1.

PMID:
21042866
3.

Clinical interpretation of residual uptake in 11C-methionine positron emission tomography after treatment of basal ganglia germ cell tumors: report of 3 cases.

Fukuoka K, Yanagisawa T, Watanabe Y, Suzuki T, Matsutani M, Kuji I, Nishikawa R.

J Neurosurg Pediatr. 2015 Oct;16(4):367-71. doi: 10.3171/2015.3.PEDS14458. Epub 2015 Jul 3.

PMID:
26140394
4.

Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M.

J Neurosurg. 2004 Sep;101(3):476-83.

PMID:
15352606
5.

[Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].

Yamaguchi S, Terasaka S, Kobayashi H, Narita T, Hirata K, Shiga S, Usui R, Tanaka S, Kubota K, Murata J, Asaoka K.

No Shinkei Geka. 2010 Jul;38(7):621-8. Japanese.

PMID:
20628188
7.

Use of PET in the diagnosis of primary CNS lymphoma in patients with atypical MR findings.

Kawai N, Okubo S, Miyake K, Maeda Y, Yamamoto Y, Nishiyama Y, Tamiya T.

Ann Nucl Med. 2010 Jun;24(5):335-43. doi: 10.1007/s12149-010-0356-z. Epub 2010 Apr 9.

PMID:
20379859
8.

Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.

Prieto E, Martí-Climent JM, Domínguez-Prado I, Garrastachu P, Díez-Valle R, Tejada S, Aristu JJ, Peñuelas I, Arbizu J.

J Nucl Med. 2011 Jun;52(6):865-72. doi: 10.2967/jnumed.110.085324. Epub 2011 May 13.

9.

Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.

Borbély K, Nyáry I, Tóth M, Ericson K, Gulyás B.

J Neurol Sci. 2006 Jul 15;246(1-2):85-94. Epub 2006 Mar 6.

PMID:
16603193
10.

Validation for performing ¹¹C-methionine and ¹⁸F-FDG-PET studies on the same day.

Mitsumoto T, Kubota K, Sato T, Morooka M, Minamimoto R, Shimbo T, Muramatsu Y, Sasaki T, Ito K, Fukushi M.

Nucl Med Commun. 2012 Mar;33(3):297-304. doi: 10.1097/MNM.0b013e32834dfa38.

PMID:
22107999
11.

Metabolic assessment of intracranial tuberculomas using 11C-methionine and 18F-FDG PET/CT.

D'Souza MM, Sharma R, Jaimini A, Panwar P, Bansal A, Tripathi M, Varshney R, Pandey S, Mondal A.

Nucl Med Commun. 2012 Apr;33(4):408-14. doi: 10.1097/MNM.0b013e32834f9b14.

PMID:
22301451
12.

Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy.

Laser BS, Merchant TE, Indelicato DJ, Hua CH, Shulkin BL, Snyder SE.

Neuro Oncol. 2013 Apr;15(4):506-10. doi: 10.1093/neuonc/nos321. Epub 2013 Feb 13.

13.

Metabolic assessment of gliomas using 11C-methionine, [18F] fluorodeoxyglucose, and 11C-choline positron-emission tomography.

Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H, Yoshimura S, Maruyama T, Muragaki Y, Iwama T.

AJNR Am J Neuroradiol. 2008 Jun;29(6):1176-82. doi: 10.3174/ajnr.A1008. Epub 2008 Apr 3.

14.

PET/CT findings for tumors in the base of the skull: comparison of 18 F-FDG with 11 C-methionine.

Tomura N, Mizuno Y, Saginoya T.

Acta Radiol. 2016 Mar;57(3):325-32. doi: 10.1177/0284185115575342. Epub 2015 Mar 19.

PMID:
25795702
15.

Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.

Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MM, Bal J, Pandey S, Kumar N, Mishra AK, Mondal A.

Clin Nucl Med. 2012 Feb;37(2):158-63. doi: 10.1097/RLU.0b013e318238f51a.

PMID:
22228339
16.

Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis.

Ng D, Jacobs M, Mantil J.

Clin Nucl Med. 2006 Jul;31(7):373-5.

PMID:
16785800
17.

Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Shiiba M, Ishihara K, Kimura G, Kuwako T, Yoshihara H, Sato H, Kondo Y, Tsuchiya S, Kumita S.

Ann Nucl Med. 2012 Feb;26(2):138-45. doi: 10.1007/s12149-011-0551-6. Epub 2011 Nov 9. Erratum in: Ann Nucl Med. 2012 Feb;26(2):146. Yoshihara, Naohisa [corrected to Yoshihara, Hisashi].

PMID:
22069194
18.

Evaluation of focal cortical dysplasia and mixed neuronal and glial tumors in pediatric epilepsy patients using 18F-FDG and 11C-methionine pet.

Phi JH, Paeng JC, Lee HS, Wang KC, Cho BK, Lee JY, Park SH, Lee J, Lee DS, Kim SK.

J Nucl Med. 2010 May;51(5):728-34. doi: 10.2967/jnumed.109.070920. Epub 2010 Apr 15.

19.

[Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].

Cai L, Gao S, Li DC, Li YS, Chen QS, Xing XL.

Zhonghua Zhong Liu Za Zhi. 2009 Feb;31(2):134-8. Chinese.

PMID:
19538892
20.

An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using 18F-FDG-PET and 11C-methionine PET.

Takahashi M, Soma T, Mukasa A, Koyama K, Arai T, Momose T.

Ann Nucl Med. 2017 Apr;31(3):250-259. doi: 10.1007/s12149-017-1153-8. Epub 2017 Feb 13.

Supplemental Content

Support Center